Posted by Michael Wonder on 08 Jul 2018
CADTH publishes initial pERC recommendation for Roche's alectinib hydrochloride
6 July 2018 - The outcome relates to the use of alectinib hydrochloride (Alecensaro) for the first-line treatment of patients with anaplastic lymphoma kinase positive, locally advanced or metastatic non-small-cell lung cancer.
The pERC has recommended the use of alectinib hydrochloride so long as its cost-effectiveness is improved to an acceptable level.
At the recommended dose of 600 mg twice daily, alectinib hydrochloride costs CAN$337.36/day and CAN$9,446.08/28 days.
